沙利度胺治疗β-地中海贫血外周血miR-223-3p水平变化及临床价值  

Change of miR-223-3p level in peripheral blood ofβ-thalassemia treated with thalidomide and corresponding clinical value

作　　者：朱卫健 何颖 黄慕芳 付社竹 王小琪 李志新 陈丽君 李小亮 Zhu Weijian;He Ying;Huang Mufang;Fu Shezhu;Wang Xiaoqi;Li Zhixin;Chen Lijun;Li Xiaoliang(Department of Hematology and Rheumatology,Zhuhai People's Hospital(Zhuhai hospital affiliated with Jinan University),Zhuhai 519000,China)

机构地区：[1]珠海市人民医院暨南大学附属珠海医院血液风湿科,广东珠海519000

出　　处：《临床荟萃》2022年第6期515-518,共4页Clinical Focus

基　　金：2020年度珠海市医疗卫生科技计划项目沙利度胺通过miRNA诱导胎儿血红蛋白治疗β-地中度海贫血的机制研究(ZH2202200041HJL)。

摘　　要：目的探讨输血依赖型β-地中海贫血患者沙利度胺治疗前后外周血单个核细胞中miR-223-3p表达水平的变化,并分析与患者血红蛋白浓度(Hb)及胎儿血红蛋白(HbF)水平的关系。方法收集8例输血依赖型β-地中海贫血患者及8例健康人的外周静脉血5ml,分离外周血单个核细胞,提取细胞总RNA,应用实时定量PCR的方法,检测口服沙利度胺有效的β-地中海贫血患者外周血单个核细胞的miR-223-3p表达水平,分析miR-223-3p与血红蛋白浓度及HbF、红细胞(RBC)、红细胞比容(Hct)、平均红细胞体积(MCV)、平均红细胞血红蛋白量(MCH)、血小板(PLT)的相关性。结果在β-地中海贫血患者外周血单个核细胞中miR-223-3p相对表达量为0.191±0.089,显著高于对照组0.053±0.039(P=0.003),口服沙利度胺后miR-223-3p相对表达量为0.106±0.047(P=0.047),表达量下降,miR-223-3p表达水平与Hb(r=-0.488,P=0.015)、HCT(r=-0.420,P=0.004)水平呈显著负相关。结论miR-223-3p在输血依赖型β-地中海贫血患者中高表达,口服沙利度胺后miR-223-3p表达水平下降,沙利度胺可能通过靶向调节miR-223-3p而改善贫血。Objective To explore the change level of miR-223-3p in peripheral blood mononuclearcell(PBMC)of patients with transfusion-dependentβthalassemia under thalidomide treatment,and to analyze its correlation with hemoglobin concentration and fetal hemoglobin(HbF).Methods The 5ml peripheral venous blood was collected from 8 patients with transfusion-dependentβthalassemia and 8 healthy subjects,PBMCs were isolated,then total RNA was extracted from the PBMCs.The effective expression level of miR-223-3p in PBMCs of patients with transfusion-dependentβthalassaemia with oral thalidomide were detected by real-time PCR,and the correlations between miR-223-3p and hemoglobin concentration,HbF,red blood cells(RBC),hematocrit(HCT)value,mean corpuscular volume(MCV),mean corpuscular hemoglobin(MCH)and platelets(PLT)were analyzed.Results The relative expression level of miR-223-3p in PBMC ofβ-thalassemia patients was 0.191±0.089,being significantly higher that of the control group at 0.053±0.039(P=0.003),and the relative expression level of miR-223-3p upon oral administration of thalidomide was 0.106±0.047(P=0.047),and the expression quantity decreased.The expression level of miR-223-3p was found inversely correlated with the level of Hb(r=-0.488,P=0.015)and HCT(r=-0.420,P=0.004).Conclusion The miR-223-3p is highly expressed in patients with transfusions dependentβthalassemia,and the expression level of miR-223-3p decreases upon oral administration of thalidomide.Thalidomide may alleviates anemia by targeting the regulation of miR-223-3p,thereby improving the anemia.

关 键 词：Β-地中海贫血 MICRO-RNA 沙利度胺 胎儿血红蛋白 

分 类 号：R556.61[医药卫生—血液循环系统疾病]